• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Office-Based Opioid Treatment
RESEARCH UPDATE

Office-Based Opioid Treatment

October 31, 2022
Joshua Blum MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Joshua Blum, MD. Dr. Blum, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

REVIEW OF: Du CX et al, Fam Pract 2022;39(2):234–240       

STUDY TYPE: Retrospective review        

There is a belief that patients taking medications for opioid use disorder (MOUD) are “complicated.” As a result, outpatient providers might be reluctant to prescribe MOUD, fearing that their practice will fill up with difficult patients. But are these patients actually more complicated? A recent study suggests that the answer is no, at least in some respects.        

Much has been written about office-based opioid treatment (OBOT) with buprenorphine, mostly in primary care, but less is known about the medical and psychiatric comorbidities of the patients who receive this treatment. Researchers conducted a retrospective chart review to determine the needs of patients enrolled in a community-based nonprofit OBOT clinic that provides primary care services. They reviewed the most recent clinic note and the last three months of urine toxicology results for all patients actively enrolled in the clinic on or before April 2019. Patients did not have to be enrolled for a given length of time to be included. Charts were excluded if patients had not received medical care at the clinic or were not prescribed buprenorphine.        

A total of 355 charts were included in the analysis. Study participants were mostly male (71.2%) and White (89%). A third (33.7%) were ≥50 years old, and two-thirds (66.1%) had been in treatment for at least one year. Common comorbidities were other substance use disorders (54.8%), psychiatric conditions (38.5%), and chronic pain (24.5%). Many (82.3%) were taking at least one medication in addition to buprenorphine, most commonly psychotropics (59.4%), particularly antidepressants (36.6%), cardiovascular medications (36.6%), and nonopioid analgesics (22.5%). The percentage of patients receiving five or more prescriptions was higher than the general US adult population (40.3% vs 15%); however, the clinical indications and types of medications were similar (Kantor ED et al, JAMA 2015;314(17):1818–1831).        

As a group, the participants were remarkably adherent, with 99.4% testing positive for prescribed buprenorphine and just 7.8% testing positive for nonprescribed opioids. Patients were not more likely to test positive for other opioids even if they had chronic pain, had psychiatric disease, or were younger. Rates of transmissible infections were low—no participants were diagnosed with HIV, and only 7.04% were diagnosed with viral hepatitis. The only factor associated with treatment retention of less than one year was a history of having an opioid-positive urine.        

The study was limited to the medical record of this specific clinic, so some medical data may not have been adequately captured. Likewise, some important outcomes were not reported, including rate of overdose, discharge from the clinic, transition to methadone, and overall patient mortality.        

Carlat Take        

The medical comorbidities of patients receiving OBOT in this study were similar to those of the general US adult population and within the scope of most primary care providers. Patients with high-risk features such as younger age, psychiatric comorbidity, and chronic pain did just as well with buprenorphine OBOT as anyone else. The study was limited to an addiction treatment facility with embedded primary care services, so how this patient population compares to the inverse—a general primary care facility that offers OBOT—is unknown. 

Addiction Treatment Research Update
KEYWORDS addiction opioid use disorder primary care psychosomatics
    Joshua Blum

    More from this author
    www.thecarlatreport.com
    Issue Date: October 31, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Trauma and Addiction
    Integrating Trauma-Informed Care into Addiction Treatment
    Office-Based Opioid Treatment
    Phenobarbital vs Lorazepam in Alcohol Withdrawal
    CME Post-Test - Trauma-Informed Care, CATR, November/December 2022
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.